Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
sopharyngitis (Common Cold) - Overview
sopharyngitis (Common Cold) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
sopharyngitis (Common Cold) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
sopharyngitis (Common Cold) - Companies Involved in Therapeutics Development
Adare Pharma Solutions
Charleston Laboratories Inc
Firebrick Pharma Pty Ltd
Pfizer Inc
SaNOtize Research and Development Corp
SSP Co Ltd
Tris Pharma Inc
sopharyngitis (Common Cold) - Drug Profiles
guaifenesin ER - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
hydrocodone bitartrate + Undisclosed drug - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IMP-1088 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NORS-1002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ORB-110 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
povidone iodine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit MAPK13 for Asthma and Cold - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ST-HT - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TRN-123 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TRN-124 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TRN-125 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sopharyngitis (Common Cold) - Dormant Projects
sopharyngitis (Common Cold) - Discontinued Products
sopharyngitis (Common Cold) - Product Development Milestones
Featured News & Press Releases
Jul 01, 2015: Spriaso Announces Approval of New Drug Application for the Long Acting Codeine Antitussive With a Popular Anti-Histamine
Oct 10, 2013: Spriaso completes FDA Meeting on Tuxarin ER
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development for Nasopharyngitis (Common Cold), 2021
Number of Products under Development by Companies, 2021
Number of Products by Targets, 2021
Number of Products by Stage and Top 10 Targets, 2021
Number of Products by Mechanism of Actions, 2021
Number of Products by Stage and Top 10 Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Stage and Molecule Types, 2021


List of Tables


Number of Products under Development for Nasopharyngitis (Common Cold), 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Products under Development by Companies, 2021
Products under Development by Universities/Institutes, 2021
Number of Products by Stage and Target, 2021
Number of Products by Stage and Mechanism of Action, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Nasopharyngitis (Common Cold) - Pipeline by Adare Pharma Solutions, 2021
Nasopharyngitis (Common Cold) - Pipeline by Charleston Laboratories Inc, 2021
Nasopharyngitis (Common Cold) - Pipeline by Firebrick Pharma Pty Ltd, 2021
Nasopharyngitis (Common Cold) - Pipeline by Pfizer Inc, 2021
Nasopharyngitis (Common Cold) - Pipeline by SaNOtize Research and Development Corp, 2021
Nasopharyngitis (Common Cold) - Pipeline by SSP Co Ltd, 2021
Nasopharyngitis (Common Cold) - Pipeline by Tris Pharma Inc, 2021
Nasopharyngitis (Common Cold) - Dormant Projects, 2021
Nasopharyngitis (Common Cold) - Discontinued Products, 2021